The Albert Einstein Cancer Center has been in the forefront of development of technologies for the analysis of gene expression, beginning with the first large scale gene array and image analysis systems developed over a decade ago, and continuing to high throughput genomics facilities for microarray analysis, mapping and sequencing, and novel technologies for quantitative in situ analysis of multiple mRNA molecules at single molecule resolution and sensitivity. An integrated program utilizing these technologies is presented that focuses on identifying subsets of Dukes' B2 and C colon cancer patients, an area of basic and clinical research in which we have been active throughout this decade. Approximately 50,000 patients per year will have adjuvant chemotherapy recommended following resection, and there is a critical need to distinguish subsets who will benefit from this treatment from subsets who either do not require further treatment, or who will not benefit, and should be spared the expense and toxicity of treatment, The latter patients with poor prognosis would also be candidates for more aggressive treatment, including gene therapy. Patients will be identified and tissue obtained through a collaborative program among the Departments of Surgery, Pathology and Oncology for capturing and following patients on clinical trials. A unique feature of our application is our development and analysis of extensive microarray databases on lineage specific differentiation of colonic epithelial cells both accompanied by, or independent of, apoptotic pathways, and our microarray analysis of isogenic colonic cell lines that over-express c-myc mRNA and protein to differing degrees. These in vitro data provide biological rationales which will help guide analyses of the in vivo data. In addition to fully operational facilities, other unique features of our program include the use of Real Time PCR for microarray calibration and quality control, and analysis of tissue obtained by laser capture microscopy; linkage to major programs in structural genomics and development and analysis of novel mouse models of colon cancer; an in place bioinformatics program which services the genomics and genetics programs of the Cancer Center; the collaboration of a biostatistics group with extensive experience in basic and translational research for the planning and analysis of the experiments; and a resource of banked normal and tumor DNA from over 700 patients entered into 2 phase III studies of adjuvant therapy for colon cancer, including the last multi- institutional study for which there is a control arm for analysis of the natural history of the disease, which will permit rigorous analysis of structural gene alterations that may underlie alterations in expression.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01CA088104-01
Application #
6196111
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (M1))
Program Officer
Lively, Tracy (LUGO)
Project Start
2000-08-28
Project End
2005-01-31
Budget Start
2000-08-28
Budget End
2001-01-31
Support Year
1
Fiscal Year
2000
Total Cost
$537,266
Indirect Cost
Name
Montefiore Medical Center (Bronx, NY)
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10467
Byun, Do-Sun; Ahmed, Naseem; Nasser, Shannon et al. (2011) Intestinal epithelial-specific PTEN inactivation results in tumor formation. Am J Physiol Gastrointest Liver Physiol 301:G856-64
Wilson, Andrew J; Chueh, Anderly C; Togel, Lars et al. (2010) Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res 70:609-20
Maier, Sandra; Daroqui, M Cecilia; Scherer, Stefan et al. (2009) Butyrate and vitamin D3 induce transcriptional attenuation at the cyclin D1 locus in colonic carcinoma cells. J Cell Physiol 218:638-42
Wilson, Andrew J; Byun, Do-Sun; Nasser, Shannon et al. (2008) HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell 19:4062-75
Li, Tianhong; Yang, Wancai; Li, Maomi et al. (2008) Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Mol Nutr Food Res 52:1289-99
Calabro, Anthony; Tai, Julia; Allen, Steven L et al. (2008) In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia. Anticancer Drugs 19:705-12
Budman, Daniel R; Tai, Julia; Calabro, Anthony (2007) Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro. Breast Cancer Res Treat 104:93-101
Budman, Daniel R; Soong, Richie; Calabro, Anthony et al. (2006) Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis. Anticancer Drugs 17:921-8
Budman, Daniel R; Calabro, Anthony (2006) Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology 70:147-53
Wilson, Andrew J; Byun, Do-Sun; Popova, Natalia et al. (2006) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281:13548-58

Showing the most recent 10 out of 25 publications